Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Codruta Chiuzan

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Cancer Immunology, Immunotherapy : CII|January 9, 2022
Combination immunotherapy including OncoVEX<sup>mGMCSF</sup> creates a favorable tumor immune micro-environment in transgenic BRAF murine melanomaRobyn D Gartrell, Zoë Blake, Emanuelle M Rizk, et al.
Journal for Immunotherapy of Cancer|December 25, 2024
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findingsBrian S Henick, Peter D Koch, Justin F Gainor, et al.
JNCI Cancer Spectrum|July 11, 2024
Prevalence of monoclonal gammopathy of undetermined significance in Eswatini: a population-based study in AfricaKara I Cicero, Xolisile Dlamini, Yvonne Mavengere, et al.
Frontiers in Oncology|September 15, 2022
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapyShaheer Khan, Jose Lutzky, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
Nature Cancer|December 30, 2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancerTizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, et al.
Muscle & Nerve|November 24, 2019
Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scaleHiroshi Mitsumoto, Codruta Chiuzan, Madison Gilmore, et al.
Oncoimmunology|May 13, 2022
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinomaRobyn D Gartrell, Thomas Enzler, Pan S Kim, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Cancer Immunology, Immunotherapy : CII|January 9, 2022
Combination immunotherapy including OncoVEX<sup>mGMCSF</sup> creates a favorable tumor immune micro-environment in transgenic BRAF murine melanomaRobyn D Gartrell, Zoë Blake, Emanuelle M Rizk, et al.
Journal for Immunotherapy of Cancer|December 25, 2024
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findingsBrian S Henick, Peter D Koch, Justin F Gainor, et al.
JNCI Cancer Spectrum|July 11, 2024
Prevalence of monoclonal gammopathy of undetermined significance in Eswatini: a population-based study in AfricaKara I Cicero, Xolisile Dlamini, Yvonne Mavengere, et al.
Frontiers in Oncology|September 15, 2022
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapyShaheer Khan, Jose Lutzky, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.
Nature Cancer|December 30, 2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancerTizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, et al.
Muscle & Nerve|November 24, 2019
Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scaleHiroshi Mitsumoto, Codruta Chiuzan, Madison Gilmore, et al.
Oncoimmunology|May 13, 2022
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinomaRobyn D Gartrell, Thomas Enzler, Pan S Kim, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Pageof 6